Health ❯ Healthcare ❯ Clinical Research

Efficacy Studies

Phase 3 Trials Phase III Trials Comparative Effectiveness Randomized Controlled Trials ESSENCE-TIMI 73b Trial HIV-1 VYVGART Placebo-Controlled Trials Patient Outcomes Weight Loss in Diabetes Agitation Management Weight Loss Interventions Pivotal Trials DELIVER Trial STEP UP Trial BaxHTN Trial VER-01 Study TRIUMPH-4 Trial ACHIEVE-3 Trial Semaglutide Trials Trial Results REPLENISH Trial HIV Prevention Strategies Preventive Treatments DREAMS-3 Trial Phase 2b Trials Survival Outcomes Endpoints in Clinical Trials Statistical Analysis Safety Assessments Novo Nordisk STARBORN-1 Trial LUCENT-3 Study Tirzepatida in Sleep Apnea Weight Loss Efficacy HIV Prevention CDR-SB Scale Higher Doses Phase 2 Trials Cardiovascular Risk Real-World Evidence TRuE-AD3 Trial STEP Trials Nebulized Tyvaso AMT-130

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Full results are slated for presentation at the American Diabetes Association meeting in June.

FDA Clears Once-Weekly Saphnelo Pen for Self-Injection in Lupus

AstraZeneca’s Tozorakimab Hits Phase III Goal in COPD, Marking Third Positive Pivotal Trial

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

Dyne’s DMD Drug Hits Primary Endpoint in DELIVER REC, Shows Functional Gains

Protara Reports Strong Interim Phase 2 Results for TARA-002 in Pediatric Lymphatic Malformations

Innovent Says Mazdutide Tops Semaglutide in China Phase 3 Diabetes Trial

EMA Panel Recommends Rejecting Rezurock for Chronic Graft-Versus-Host Disease in EU

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

Cannabis Extract VER-01 Eases Chronic Low Back Pain in Phase 3 Trial

Cochrane Review Finds RSV Vaccines Protect Older Adults and Infants Without Raising Serious Risks

Moonlake Shares Plunge on Mixed Phase 3 Results for Hidradenitis Drug

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Ionis’ Olezarsen Slashes Triglycerides, Cuts Pancreatitis in Phase 3 Trials